Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Can-Fite BioPharma, a biotechnology company, has completed enrollment of 80 patients in its Phase II dry eye syndrome trial.
Subscribe to our email newsletter
Approximately 80 patients were enrolled to this study, randomized into two groups treated with 1mg of CF101 and placebo. Patients are taking the drug for 12 weeks plus two weeks of follow-up. The trial is being conducted in six sites in Israel. The company expects to release study data in the second quarter of 2009.
In addition, the company recently announced that it has signed an out licensing agreement with Kwang Dong Pharmaceutical Co, a Korean company, granting Kwang Dong exclusive rights to develop and commercialize the drug CF101 for rheumatoid arthritis, in Korea.
CF101, Can-Fite’s lead drug, is currently being tested in a multi-national Phase IIb study for its therapeutic activity in the treatment of rheumatoid arthritis and in two Phase IIa studies: one for the treatment of psoriasis and the other for dry eye syndrome.